|“572-Trii”||dolutegravir / abacavir / lamivudine, or DTG / ABC / 3TC|
|BRAND NAME NOT YET ESTABLISHED||GENERIC NAME|
|CLASS:||STR: Single-Tablet Regimen—INSTI and NRTIs|
ViiV Healthcare| www.viivhealthcare.com | (877) 844-8872
TBD; investigational drug at press time
Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.
See the individual drugs contained in “572-Trii”: dolutegravir, Ziagen, and Epivir. Available data are limited due to investigational drug status.
See the individual drugs contained in “572-Trii”: dolutegravir, Ziagen, and Epivir. Tell your provider or pharmacist about all medications, herbs, and supplements you are taking or thinking of taking, prescribed or not. Dolutegravir has no effect on midazolam, tenofovir, rilpivirine, methadone, and oral contraceptives. Reyataz increases dolutegravir levels while Prezista, Lexiva, Aptivus Sustiva, and rifabutin have been shown to decrease it by anywhere from 30-75%, and Intelence decreases it by 88%. This interaction can counteracted by the addition of Kaletra or ritonavir-boosted Prezista. Antacids need to be separated from dolutegravir by at least two hours. This is due to what is called metal cation chelation (meaning that magnesium, aluminum and calcium in antacids bind to dolutegravir and keep it from being absorbed). Non-antacid acid reflux/heartburn medications are okay to use as no change in dolutegravir levels was seen with omeprazole. More drug interactions are anticipated, but data are limited right now due to investigational drug status.
The single tablet regimen (“572-Trii”) containing dolutegravir, abacavir, and lamivudine is currently being studied. “572-Trii” is pronounced “572-try.” See the individual drugs contained in “572-Trii”—dolutegravir, Ziagen, and Epivir—for more information. Dolutegravir is a second-generation INSTI, meaning that it can work in many individuals whose virus has developed resistance to Isentress and elvitegravir, but it will need to be dosed twice daily in these individuals. Based on the current data, “572-Trii” appears to be an exciting addition to the current antiretrovirals. It gives us another single tablet complete regimen. There will be twice-daily dosing for patients with INSTI drug resistance. It will have fewer drug interactions than Stribild and appears to be well tolerated; most patients stayed on treatment despite reports of more than 10% experiencing nausea and diarrhea. Does not require use with a booster medication as does elvitegravir (see elvitegravir). The ongoing SINGLE study, in patients who are treatment-naïve (meaning that they have never been on HIV medications before), demonstrated superiority of dolutegravir/Epzicom compared to the single tablet regimen Atripla. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (less than 50 copies/mL) vs. 81% of participants on Atripla. Differences in the slightly better outcomes for dolutegravir were mostly driven by a higher rate of discontinuation due to side effects in the Atripla group. Dolutegravir is expected to receive FDA approval this year (see dolutegravir page). See package insert, when available, for more complete information on potential side effects and interactions.